Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
DiaMedica Therapeutics Inc. DMAC
$1.60
-$0.02 (-1.23%)
На 18:01, 12 мая 2023
+525.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
44215830.00000000
-
week52high
2.61
-
week52low
1.12
-
Revenue
0
-
P/E TTM
-3
-
Beta
1.73944600
-
EPS
-0.52000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 21:00
Описание компании
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Perform | Outperform | 07 июл 2022 г. |
| Lake Street | Buy | Buy | 07 июл 2022 г. |
| Craig-Hallum | Buy | Buy | 07 июл 2022 г. |
| Roth Capital | Buy | Buy | 30 июн 2021 г. |
| Oppenheimer | Outperform | 09 апр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Giuffre Randall Michael | A | 295355 | 35130 | 03 янв 2023 г. |
| Burroughs Amy L. | A | 73288 | 17156 | 03 янв 2023 г. |
| Semba Charles Pauling | A | 17156 | 17156 | 03 янв 2023 г. |
| Pilnik Richard D. | A | 209882 | 55555 | 03 янв 2023 г. |
| Giuffre Randall Michael | A | 260225 | 37079 | 09 дек 2022 г. |
| Giuffre Randall Michael | A | 223146 | 20000 | 08 дек 2022 г. |
| Giuffre Randall Michael | A | 203146 | 22574 | 07 дек 2022 г. |
| Giuffre Randall Michael | A | 180572 | 2300 | 06 дек 2022 г. |
| Pilnik Richard D. | A | 154327 | 35000 | 05 дек 2022 г. |
| Von Koch Thomas | A | 2855847 | 2855847 | 02 дек 2022 г. |
Новостная лента
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
Business Wire
08 мая 2023 г. в 08:50
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15th. DiaMedica will host a live conference call on Tuesday, May 16th at 7:00 AM Central Time to provide a business update and discuss financial results. Conferenc.
DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript
Seeking Alpha
29 мар 2023 г. в 10:01
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Kirsten Gruis - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics ReMEDy2 Update Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
Business Wire
20 мар 2023 г. в 16:17
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th. DiaMedica will host a live conference call on Wednesday, March 29th at 7:00 AM Central Time to provide a business update and discuss financial results.
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Business Wire
13 мар 2023 г. в 08:00
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33rd Annual Healthcare Conference, which will take place March 13th – 15th, 2023. Mr. Pauls is scheduled to present at 2:40 p.m. Eastern Time on Wednesday, March 15, 2023.
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
Zacks Investment Research
02 ноя 2022 г. в 13:33
DiaMedica Therapeutics, Inc. (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).